Dermazyn

Probiotic Solution for Pediatric Atopic Dermatitis

KEY MARKETING ASPECTS

  • targeting the most frequent allergic disease in children
  • unique combination of patented probiotic strains selected for the treatment of atopic dermatitis and for restoring the allergic immune system
  • plus vitamin D – health claim related to the normal function of the immune system and inflammatory response (eU no 432/2012)
  • 50% less allergy symptoms (pruritus, sleep loss, redness, swelling)
  • less emotional stress
  • alternative or add-on therapy to corticosteroids
  • clinically tested in children
  • high acceptance in children
  • most efficient probiotic solution available for the treatment of atopic dermatitis
  • pharmacy exclusive

Facts

  • randomized, placebo-controlled clinical trial (RCT) demonstrating significant reduction in clinical symptoms of atopic dermatitis in children1
  • additional 3 RCTs published demonstrating improvements of other allergy symptoms2,3,4
  • vitamin D modulates the immune response and helps alleviating symptoms of atopic dermatitis5
  • stimulating the Th1 immune response (Inf-γ)6 and reducing key mediators (IL-4 & Ige) of allergic response1
  • highest clinical efficacy of probiotic treatments for dermatitis7

HOW TO USE

  • lozenge: children above 3 years of age
  • sachet: children under 3 years of age
  • once a day
  • add-on to emollient & topical corticosteroids


 

References

  1. Wang & Wang, Clin exp Allergy (2015)
  2. Costa et al., eur J Clin nutr (2014)
  3. Peng et al., Pediatr Allergy Immunol (2005)
  4. Wang et al., Pediatr Allergy Immunol (2004),
  5. Mutgi & Koo, Pediatr Dermatol (2013)
  6. Lu et al., eP 2,581,461B1 (2011)
  7. Huang et al., front Cell Infect Microbiol 7 (2017)

Dermazyn is a registered trademark by BLUESTONE PHARMA GmbH | contact: info@bluestone-pharma.com